SEPN
Septerna, Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.69
−2.05%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$38.43
From 52W high−19.71%
Volume437415.00
Market cap$1.81B
P/E (TTM)—
P/S (TTM)18.3x
Div yield—
Key dataSep 18, 2026
Open
$38.43
From 52W high
−19.71%
Volume
437415.00
Market cap
$1.81B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−36.6x
P/E (TTM)
—
RSI (14)
47.1
MomentumView details →
1D Return
−2.05%
YTD Return
+36.63%
SummaryUpdated Jun 1, 2026
Septerna, Inc. (NASDAQ:SEPN) is a clinical-stage biotechnology company founded in 2019 and headquartered in South San Francisco, California. Originally incorporated as GPCR NewCo, Inc., the company changed its name to Septerna Inc. in June 2021 and went public in October 2024. Septerna focuses on discovering and developing oral small molecule drug candidates that target G protein-coupled receptors (GPCRs) for treating endocrinology, immunology, inflammation, and metabolic diseases.
Similar companies
Latest newsMore news →
RA Capital Management, L.P., a significant shareholder and director of Septerna, Inc., sold 1,493,000 shares of Septerna common stock for $63,452,500 on August 12, 2026.37d agoSepterna, Inc. reported a second-quarter net loss of $0.29 per share, beating the Zacks Consensus Estimate of a $0.48 loss and improving from a $0.56 loss a year earlier.41d ago